ClinicalTrials.gg
CompletedNCT01473420AiME - 13Updated Aug 9, 2018Results posted

A Phase 3 Study Comparing the Effects of Subcutaneous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin

A Phase 3 interventional study of Epoetin Hospira and Epogen Amgen in Chronic Renal Failure and Chronic Kidney Disease, sponsored by Pfizer. Completed at 73 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-08-09.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
320
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing Epoetin Alfa in Kidney Failure, Chronic — none open to participants now, none under way, none of them phase 3. Epoetin Alfa · Kidney Failure, Chronic.

Enrollment
6th of 13
320 · median 292
Started
2012
with 4 others
Phase 3
5 of 13
none open now
Registered
9th of 13
by date
Lead sponsor
4 of 13
Pfizer

Among the 13 studies testing Epoetin Alfa in Kidney Failure, Chronic, this one is the 6th largest by enrollment, is one of 5 that started in 2012, is one of 5 in phase 3, and was the 9th registered.

Kidney Failure, Chronic

2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

None of the 13 studies testing Epoetin Alfa in Kidney Failure, Chronic is open now. The open studies under Kidney Failure, Chronic, anywhere →

Where they have run

About Epoetin Alfa

Epoetin Alfa: first FDA approval 1989 (EPOGEN/PROCRIT), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies testing Epoetin Alfa in Kidney Failure, Chronic as a file.
02

Study summary

The purpose of this study is to demonstrate therapeutic equivalence of subcutaneous (SC) Epoetin Hospira compared to SC Epogen (Amgen), based on maintenance of hemoglobin (Hb) levels and study drug dose requirements in patients treated for anemia associated with chronic renal failure and on hemodialysis.

03

Conditions studied

  • Chronic Renal Failure
  • Chronic Kidney Disease
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient is able to provide written after risks and benefits of the study have been explained prior to any study related activities
  2. Hemodialysis patients with chronic renal failure and renal anemia currently on stable Epogen (Amgen) dose administered IV or SC, 1 to 3 times per week for whom the following apply:

    • A change in Epogen dosing of no more than 10% from the mean
    • Mean between 9.0 and 11.0 g/dL
    • No more than one hemoglobin result outside of range from 9.0-11.0 g/dL
    • No hemoglobin result more than ±1 g/dL from the mean hemoglobin level
  3. Patients on stable, adequate dialysis for at least 12 weeks prior to randomization, defined as no changes of dialysis regimen and/or dialyzer
  4. Patients with adequate iron stores, defined as plasma ferritin > 100 μg/L and TSAT >20%, prior to randomization
  5. Male or female patients aged 18 to 80 years (both inclusive)
  6. If female, patient must be for at least one year prior to randomization, surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy), or practicing at least one of the following methods of :

    • hormonal contraceptives (oral, parenteral or transdermal) for at least 3 months prior to randomization
    • intrauterine device (IUD)
    • double-barrier method (condoms, contraceptive sponge, diaphragm or vaginal ring with spermicidal jellies or cream)

If hormonal contraceptives are used, the specific contraceptive must have been used for at least 3 months prior to randomization. If the patient is currently using a hormonal contraceptive, she should also use a barrier method during this study and for at least 30 days following the administration of the patient's last dose

Exclusion criteria

Exclusion Criteria:

  1. Maintenance epoetin dosage >600 U/kg per week (1-3 times per week)
  2. Treatment with long-acting epoetin analogues such as Aranesp ® within 12 weeks prior to randomization
  3. Any of the following within 3 months prior to randomization:

    • Myocardial infarction
    • Stroke (cerebrovascular accident)/cerebrovascular insult (minor stroke) or /intracerebral bleeding/cerebral infarction
    • Severe/unstable angina
    • Coronary angioplasty, bypass surgery, or peripheral artery bypass graft
    • Decompensated congestive heart failure ( [NYHA] class IV)
    • Pulmonary embolism
    • Deep vein thrombosis or other thromboembolic event
    • Received live or attenuated vaccination (except flu vaccination)
  4. Uncontrolled hypertension within the 4 weeks prior to randomization defined as more than 10% of post-dialysis blood pressures >170 mmHg systolic and/or >110 mmHg diastolic, based on blood pressure readings obtained when the patient's post-dialysis body weight was not more than 0.5 kg above their listed dry weight
  5. Known, clinically manifested deficiency of folic acid and/or vitamin B12 (irrespective of whether currently treated or not)
  6. A patient with any active, uncontrolled systemic, inflammatory or malignant disease that in the Investigator's opinion may be significant to exclude participation in the study, including but not limited to demyelinating diseases such as multiple sclerosis, microbial, viral or fungal infection or mental disease
  7. for the test drug or have been previously treated with Epoetin Hospira
  8. Relative or absolute iron deficiency prior to randomization into the Maintenance Period
  9. count below 100 x 10\^9/L
  10. increase of CRP (>10 mg/dL) for at least 2 weeks
  11. Significant drug sensitivity or a significant allergic reaction to any drug, as well as known or idiosyncratic reaction to epoetin (or its , including albumin) or any other related drugs that in the judgment of the Investigator is exclusionary for the study participation
  12. History of any of the following:

    • Detectable anti-rhEPO antibodies
    • Clinically relevant malnutrition
    • Confirmed aluminum intoxication
    • Myelodysplastic syndrome
    • Known bone marrow fibrosis (osteitis fibrosa cystica)
    • Known seizure disorder
    • Liver cirrhosis with clinical evidence of complications (portal hypertension, splenomegaly, ascites)
  13. A female patient who is pregnant, lactating or planning a pregnancy during the study
  14. History of drug abuse or alcohol abuse within 2 years prior to randomization as determined by the Investigator
  15. Current participation or participation in a drug or other research study within 30 days prior to randomization
  16. May not be able to comply with the requirements of this clinical study, communicate effectively with study personnel, or is considered by the Investigator, for any reason, to be an unsuitable candidate for the study
  17. Donated or lost >475 mL (i.e., 1 pint) blood volume (including plasmapheresis) or had a transfusion of any blood product within 3 months prior to randomization
  18. A patient who in the Investigator's opinion, has any clinically significant abnormal laboratory evaluations, including liver function taken at Screening Visit
  19. Positive laboratory test for (HIV) or surface antigen (HBsAg)
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
320 participants (actual)

Study arms

  • Experimental
    Epoetin Hospira

    Epoetin Hospira

    Biological: Epoetin Hospira

  • Active comparator
    Epogen (Amgen)

    Epogen (Amgen)

    Biological: Epogen Amgen

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Weekly Hemoglobin Level From Week 30 to Week 34: Maintenance Period

    Time frame: Week 30 up to Week 34

  2. Mean Weekly Dosage of Study Medication From Week 30 to Week 34: Maintenance Period

    Time frame: Week 30 up to Week 34

Secondary outcomes

  1. Mean Weekly Hemoglobin Level From Week 19 to Week 34: Maintenance Period

    Time frame: Week 19 up to Week 34

  2. Mean Weekly Dosage of Study Medication From Week 19 to Week 34: Maintenance Period

    Time frame: Week 19 up to Week 34

  3. Total Dose of Study Medication Administered: Maintenance Period

    In this outcome measure mean of total dose of study medication administered in maintenance period was reported.

    Time frame: Week 19 up to Week 34

  4. Percentage of Participants With Mean Weekly Hemoglobin Level Within the Target Range: Maintenance Period

    Percentage of participants who had hemoglobin level within the target range of 9 to 11 g/dL for the specified weeks were reported.

    Time frame: Week 26, 34

  5. Percentage of Participants Who Required Permanent Dose Changes: Maintenance Period

    Time frame: Week 19 up to Week 34

  6. Percentage of Participants Who Required Temporary Dose Changes: Maintenance Period

    Time frame: Week 19 up to Week 34

  7. Percentage of Participants With Any Transient Change of Hemoglobin Level Greater Than (>) 1.0 Gram Per Deciliter (g/dL): Maintenance Period

    Time frame: Week 19 up to Week 34

  8. Percentage of Participants With Mean Weekly Hemoglobin Level Outside the Target Range: Maintenance Period

    Percentage of participants who had hemoglobin level outside the target range of 9 to 11 g/dL for the specified weeks were reported.

    Time frame: Week 26, 34

  9. Percentage of Participants Who Qualified as Optimally Titrated and Stable: Titration Period

    Time frame: Week 1 up to Week 18

  10. Percentage of Participants Who Received Blood Transfusions: Maintenance Period

    Time frame: Week 19 up to Week 34

  11. Number of Participants With Change in Mean Dose of Study Medication Based on Hemoglobin Level: Maintenance Period

    In this outcome measure number of participants with change (increase and decrease) in mean dose of Epoetin Hospira and Epogen were categorized and reported according to their mean hemoglobin levels. Hemoglobin levels were divided in following classes: \>11.0 g/dL, from 9.0 to 11.0 g/dL and \<9.0 g/dL

    Time frame: Week 19 up to Week 34

  12. Percentage of Participants With Any Transient Change of Hemoglobin Level Greater Than (>) 2.0 Gram Per Deciliter (g/dL) in Hemoglobin Level: Maintenance Period

    Time frame: Week 19 up to Week 34

Other outcomes

  1. Percentage of Participants With Hemoglobin Level Less Than (<) 8.0 Gram Per Deciliter (g/dL): Maintenance Period

    Time frame: Week 19 up to Week 34

  2. Percentage of Participants With Hemoglobin Level Greater Than (>) 12.0 Gram Per Deciliter (g/dL): Maintenance Period

    Time frame: Week 19 up to Week 34

  3. Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pretreatment state. AEs included both serious and non-serious adverse events.

    Time frame: Titration Period: Week 1 up to Week 18 and Maintenance Period: Week 19 up to Week 38

  4. Number of Participants With Treatment-Emergent Adverse Events by Severity

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pretreatment state. An AE was assessed according to severity; mild (AE was transient and easily tolerated by the participant), moderate (caused problem that did not interfere significantly with usual activities) and severe (caused problem that interferes significantly with usual activities and might be incapacitating or life-threatening).

    Time frame: Titration Period: Week 1 up to Week 18 and Maintenance Period: Week 19 up to Week 38

  5. Number of Participants With Treatment Related Adverse Events (AEs)

    An AE was any untoward medical occurrence in a participant who received study drug.

    Time frame: Titration Period: Week 1 up to Week 18 and Maintenance Period: Week 19 up to Week 38

  6. Number of Participants That Discontinued Treatment Due to a Treatment Emergent Adverse Event

    In this outcome measure number of participants discontinued from study drug (Epoetin Hospira, Epogen) due to any AE were reported.

    Time frame: Titration Period: Week 1 up to Week 18 and Maintenance Period: Week 19 up to Week 38

  7. Number of Participants With Clinically Significant Change From Baseline in Laboratory Parameters

    Laboratory parameters: Hematology (hematocrit, hemoglobin, red blood cell count, reticulocytes, white blood cell count, neutrophils, bands, lymphocytes, monocytes, basophils, eosinophils, platelet count, mean corpuscular volume); coagulation panel (prothrombin time, international normalized ratio, activated partial thromboplastin time); clinical chemistry (blood urea nitrogen, creatinine, alanine aminotransferase, aspartate aminotransferase, total bilirubin, gamma-glutamyl transpeptidase, alkaline phosphatase, sodium, potassium, calcium, magnesium, phosphorus, uric acid, total protein, glucose, albumin, C-reactive protein, plasma ferritin, transferrin saturation). Participants with clinically significant change from baseline in laboratory parameters were as determined by the investigator.

    Time frame: Titration Period: Baseline (Pre-dose on Week 1) up to Week 18 and Maintenance Period: Baseline (Pre-dose on Week 19) up to Week 38

  8. Number of Participants With Clinically Significant Change From Baseline in Vital Signs

    Vital sign parameters: temperature (oral, tympanic, or other), blood pressure (diastolic and systolic), heart rate (in a seated position) and dry weight (post-dialysis). Participants with clinically significant change from baseline in vital signs were as determined by the investigator.

    Time frame: Titration Period: Baseline (Pre-dose on Week 1) up to Week 18 and Maintenance Period: Baseline (Pre-dose on Week 19) up to Week 38

  9. Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG)

    ECG parameters: PR interval, QRS complex, QT interval and QTC interval. Participants with clinically significant change from baseline in ECG were as determined by the investigator.

    Time frame: Titration Period: Baseline (Pre-dose on Week 1) up to Week 18 and Maintenance Period: Baseline (Pre-dose on Week 19) up to Week 38

  10. Number of Participants With Clinically Significant Change From Baseline in Physical Examination

    Physical examination included examination of the following: skin, eyes, ears, throat, cardiac, respiratory, gastrointestinal, genitourinary and musculoskeletal systems. Participants with clinically significant change from baseline in physical examination were as determined by the investigator.

    Time frame: Titration Period: Baseline (Pre-dose on Week 1) up to Week 18 and Maintenance Period: Baseline (Pre-dose on Week 19) up to Week 38

  11. Percentage of Participants With Anti-Recombinant Human Erythropoietin (Anti-rhEPO) Antibodies

    Percentage of participants with presence of anti-rhEPO antibodies were reported in this outcome measure. Radioimmunoprecipitation assay method was used to determine the presence of anti-rhEPO antibodies.

    Time frame: Titration Period: Week 1 up to Week 18 and Maintenance Period: Week 19 up to Week 38

  12. Percentage of Participants With General Tolerability

    General tolerability was classified as: 1) excellent tolerability = no reaction, 2) good tolerability = minimal reaction, 3) mild intolerability = reaction above that normally observed with any kind of subcutaneous product, 4) moderate intolerability = marked reaction, but no need for discontinuation of treatment and 5) severe intolerability = treatment discontinued due to intolerability.

    Time frame: Titration Period: Week 1 up to Week 18 and Maintenance Period: Week 19 up to Week 38

  13. Percentage of Participants With Local Tolerability

    Local tolerability was classified as: 1) excellent tolerability = no reaction at site of injection, 2) good tolerability = minimal reaction at site of injection normally observed with any kind of subcutaneous product, 3) mild intolerability = reaction at site of injection above that normally observed with any kind of subcutaneous product, 4) moderate intolerability = marked reaction, but no need for discontinuation of treatment and 5) severe intolerability = treatment discontinued due to intolerability.

    Time frame: Titration Period: Week 1 up to Week 18 and Maintenance Period: Week 19 up to Week 38

07

Results

Posted Jun 20, 2018

Participant flow

Participants with chronic renal failure were receiving Epoetin maintenance therapy prior to enrollment and treatment in this study.

Titration Period (18 Weeks)
Participant flow — Titration Period (18 Weeks)
MilestoneEpoetin HospiraEpogen
Started160160
Treated8086
Completed124122
Not completed3638
Withdrew: Adverse event46
Withdrew: Did not meet criteria3232
Maintenance Period (16 Weeks)
Participant flow — Maintenance Period (16 Weeks)
MilestoneEpoetin HospiraEpogen
Started124122
Completed106105
Not completed1817
Withdrew: Adverse event32
Withdrew: Physician decision12
Withdrew: Did not meet criteria02
Withdrew: Kidney transplant31
Withdrew: Lost to follow-up12
Withdrew: Withdrawal by subject46
Withdrew: Site closure31
Withdrew: Started peritoneal dialysis10
Withdrew: Long term hospitalization01
Withdrew: Sponsor's decision10
Withdrew: Elevated hemoglobin10

Outcome measures

PrimaryMean Weekly Hemoglobin Level From Week 30 to Week 34: Maintenance Period
Time frame:
Week 30 up to Week 34
Reported as:
Mean · g/dL
Mean Weekly Hemoglobin Level From Week 30 to Week 34: Maintenance Period
g/dLEpoetin Hospira: Maintenance PeriodEpogen: Maintenance Period
Mean Weekly Hemoglobin Level From Week 30 to Week 34: Maintenance Period10.17 ± 0.82110.11 ± 0.838
Statistical analysis
  • Epoetin Hospira: Maintenance Period vs Epogen: Maintenance Period · Ls mean difference: 0.04 · 95% CI -0.17 to 0.24
PrimaryMean Weekly Dosage of Study Medication From Week 30 to Week 34: Maintenance Period
Time frame:
Week 30 up to Week 34
Reported as:
Mean · unit per kilogram per week (U/kg/week)
Mean Weekly Dosage of Study Medication From Week 30 to Week 34: Maintenance Period
unit per kilogram per week (U/kg/week)Epoetin Hospira: Maintenance PeriodEpogen: Maintenance Period
Mean Weekly Dosage of Study Medication From Week 30 to Week 34: Maintenance Period82.07 ± 95.51779.14 ± 82.264
Statistical analysis
  • Epoetin Hospira: Maintenance Period vs Epogen: Maintenance Period · Ls mean difference: -2.34 · 95% CI -14.51 to 9.82
SecondaryMean Weekly Hemoglobin Level From Week 19 to Week 34: Maintenance Period
Time frame:
Week 19 up to Week 34
Reported as:
Mean · g/dL
Mean Weekly Hemoglobin Level From Week 19 to Week 34: Maintenance Period
g/dLEpoetin Hospira: Maintenance PeriodEpogen: Maintenance Period
Mean Weekly Hemoglobin Level From Week 19 to Week 34: Maintenance Period10.20 ± 0.62510.22 ± 0.665
Statistical analysis
  • Epoetin Hospira: Maintenance Period vs Epogen: Maintenance Period · Two-sample t-test · p = 0.8338
SecondaryMean Weekly Dosage of Study Medication From Week 19 to Week 34: Maintenance Period
Time frame:
Week 19 up to Week 34
Reported as:
Mean · U/kg/week
Mean Weekly Dosage of Study Medication From Week 19 to Week 34: Maintenance Period
U/kg/weekEpoetin Hospira: Maintenance PeriodEpogen: Maintenance Period
Mean Weekly Dosage of Study Medication From Week 19 to Week 34: Maintenance Period81.93 ± 93.82475.08 ± 72.174
Statistical analysis
  • Epoetin Hospira: Maintenance Period vs Epogen: Maintenance Period · Wilcoxon Rank Sum test · p = 0.6895P-value was calculated from a Wilcoxon Rank Sum test and t-approximation was used.
SecondaryTotal Dose of Study Medication Administered: Maintenance Period

In this outcome measure mean of total dose of study medication administered in maintenance period was reported.

Time frame:
Week 19 up to Week 34
Reported as:
Mean · units of study medication
Total Dose of Study Medication Administered: Maintenance Period
units of study medicationEpoetin Hospira: Maintenance PeriodEpogen: Maintenance Period
Total Dose of Study Medication Administered: Maintenance Period102003.2 ± 135560.5286478.5 ± 83351.03
Statistical analysis
  • Epoetin Hospira: Maintenance Period vs Epogen: Maintenance Period · Wilcoxon Rank Sum test · p = 0.9177P-value was calculated from a Wilcoxon Rank Sum test and t-approximation was used.
SecondaryPercentage of Participants With Mean Weekly Hemoglobin Level Within the Target Range: Maintenance Period

Percentage of participants who had hemoglobin level within the target range of 9 to 11 g/dL for the specified weeks were reported.

Time frame:
Week 26, 34
Reported as:
Number · percentage of participants
Percentage of Participants With Mean Weekly Hemoglobin Level Within the Target Range: Maintenance Period
percentage of participantsEpoetin Hospira: Maintenance PeriodEpogen: Maintenance Period
Week 2673.560.9
Week 3479.874.0
SecondaryPercentage of Participants Who Required Permanent Dose Changes: Maintenance Period
Time frame:
Week 19 up to Week 34
Reported as:
Number · percentage of participants
Percentage of Participants Who Required Permanent Dose Changes: Maintenance Period
percentage of participantsEpoetin Hospira: Maintenance PeriodEpogen: Maintenance Period
Percentage of Participants Who Required Permanent Dose Changes: Maintenance Period30.225.0
SecondaryPercentage of Participants Who Required Temporary Dose Changes: Maintenance Period
Time frame:
Week 19 up to Week 34
Reported as:
Number · percentage of participants
Percentage of Participants Who Required Temporary Dose Changes: Maintenance Period
percentage of participantsEpoetin Hospira: Maintenance PeriodEpogen: Maintenance Period
Percentage of Participants Who Required Temporary Dose Changes: Maintenance Period55.862.0
SecondaryPercentage of Participants With Any Transient Change of Hemoglobin Level Greater Than (>) 1.0 Gram Per Deciliter (g/dL): Maintenance Period
Time frame:
Week 19 up to Week 34
Reported as:
Number · percentage of participants
Percentage of Participants With Any Transient Change of Hemoglobin Level Greater Than (>) 1.0 Gram Per Deciliter (g/dL): Maintenance Period
percentage of participantsEpoetin Hospira: Maintenance PeriodEpogen: Maintenance Period
Percentage of Participants With Any Transient Change of Hemoglobin Level Greater Than (>) 1.0 Gram Per Deciliter (g/dL): Maintenance Period29.152.2
SecondaryPercentage of Participants With Mean Weekly Hemoglobin Level Outside the Target Range: Maintenance Period

Percentage of participants who had hemoglobin level outside the target range of 9 to 11 g/dL for the specified weeks were reported.

Time frame:
Week 26, 34
Reported as:
Number · percentage of participants
Percentage of Participants With Mean Weekly Hemoglobin Level Outside the Target Range: Maintenance Period
percentage of participantsEpoetin Hospira: Maintenance PeriodEpogen: Maintenance Period
Week 2613.519.3
Week 3410.113.0
SecondaryPercentage of Participants Who Qualified as Optimally Titrated and Stable: Titration Period
Time frame:
Week 1 up to Week 18
Reported as:
Number · percentage of participants
Percentage of Participants Who Qualified as Optimally Titrated and Stable: Titration Period
percentage of participantsEpoetin Hospira: Titration PeriodEpogen: Titration Period
Percentage of Participants Who Qualified as Optimally Titrated and Stable: Titration Period47.547.7
SecondaryPercentage of Participants Who Received Blood Transfusions: Maintenance Period
Time frame:
Week 19 up to Week 34
Reported as:
Number · percentage of participants
Percentage of Participants Who Received Blood Transfusions: Maintenance Period
percentage of participantsEpoetin Hospira: Maintenance PeriodEpogen: Maintenance Period
Percentage of Participants Who Received Blood Transfusions: Maintenance Period4.04.1
SecondaryNumber of Participants With Change in Mean Dose of Study Medication Based on Hemoglobin Level: Maintenance Period

In this outcome measure number of participants with change (increase and decrease) in mean dose of Epoetin Hospira and Epogen were categorized and reported according to their mean hemoglobin levels. Hemoglobin levels were divided in following classes: \>11.0 g/dL, from 9.0 to 11.0 g/dL and \<9.0 g/dL

Time frame:
Week 19 up to Week 34
Reported as:
Count of participants · Participants
Number of Participants With Change in Mean Dose of Study Medication Based on Hemoglobin Level: Maintenance Period
ParticipantsEpoetin Hospira: Maintenance PeriodEpogen: Maintenance Period
Dose Decrease: Hb <9.0 g/dL910
Dose Decrease: Hb (9.0 to 11.0 g/dL)2014
Dose Decrease: Hb >11.0 g/dL3540
Dose Increase: Hb <9.0 g/dL2423
Dose Increase: Hb (9.0 to 11.0 g/dL)113
Dose Increase: Hb >11.0 g/dL713
SecondaryPercentage of Participants With Any Transient Change of Hemoglobin Level Greater Than (>) 2.0 Gram Per Deciliter (g/dL) in Hemoglobin Level: Maintenance Period
Time frame:
Week 19 up to Week 34
Reported as:
Number · percentage of participants
Percentage of Participants With Any Transient Change of Hemoglobin Level Greater Than (>) 2.0 Gram Per Deciliter (g/dL) in Hemoglobin Level: Maintenance Period
percentage of participantsEpoetin Hospira: Maintenance PeriodEpogen: Maintenance Period
Percentage of Participants With Any Transient Change of Hemoglobin Level Greater Than (>) 2.0 Gram Per Deciliter (g/dL) in Hemoglobin Level: Maintenance Period6.610.7
Other pre-specifiedPercentage of Participants With Hemoglobin Level Less Than (<) 8.0 Gram Per Deciliter (g/dL): Maintenance Period
Time frame:
Week 19 up to Week 34
Reported as:
Number · percentage of participants
Percentage of Participants With Hemoglobin Level Less Than (<) 8.0 Gram Per Deciliter (g/dL): Maintenance Period
percentage of participantsEpoetin Hospira: Maintenance PeriodEpogen: Maintenance Period
Percentage of Participants With Hemoglobin Level Less Than (<) 8.0 Gram Per Deciliter (g/dL): Maintenance Period4.19.0
Other pre-specifiedPercentage of Participants With Hemoglobin Level Greater Than (>) 12.0 Gram Per Deciliter (g/dL): Maintenance Period
Time frame:
Week 19 up to Week 34
Reported as:
Number · percentage of participants
Percentage of Participants With Hemoglobin Level Greater Than (>) 12.0 Gram Per Deciliter (g/dL): Maintenance Period
percentage of participantsEpoetin Hospira: Maintenance PeriodEpogen: Maintenance Period
Percentage of Participants With Hemoglobin Level Greater Than (>) 12.0 Gram Per Deciliter (g/dL): Maintenance Period9.819.7
Other pre-specifiedNumber of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pretreatment state. AEs included both serious and non-serious adverse events.

Time frame:
Titration Period: Week 1 up to Week 18 and Maintenance Period: Week 19 up to Week 38
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsEpoetin Hospira: Titration PeriodEpogen: Titration PeriodEpoetin Hospira: Maintenance PeriodEpogen: Maintenance Period
AEs45548586
SAEs12222333
Other pre-specifiedNumber of Participants With Treatment-Emergent Adverse Events by Severity

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pretreatment state. An AE was assessed according to severity; mild (AE was transient and easily tolerated by the participant), moderate (caused problem that did not interfere significantly with usual activities) and severe (caused problem that interferes significantly with usual activities and might be incapacitating or life-threatening).

Time frame:
Titration Period: Week 1 up to Week 18 and Maintenance Period: Week 19 up to Week 38
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events by Severity
ParticipantsEpoetin Hospira: Titration PeriodEpogen: Titration PeriodEpoetin Hospira: Maintenance PeriodEpogen: Maintenance Period
Mild21234241
Moderate15162427
Severe9151918
Other pre-specifiedNumber of Participants With Treatment Related Adverse Events (AEs)

An AE was any untoward medical occurrence in a participant who received study drug.

Time frame:
Titration Period: Week 1 up to Week 18 and Maintenance Period: Week 19 up to Week 38
Reported as:
Count of participants · Participants
Number of Participants With Treatment Related Adverse Events (AEs)
ParticipantsEpoetin Hospira: Titration PeriodEpogen: Titration PeriodEpoetin Hospira: Maintenance PeriodEpogen: Maintenance Period
Number of Participants With Treatment Related Adverse Events (AEs)14711
Other pre-specifiedNumber of Participants That Discontinued Treatment Due to a Treatment Emergent Adverse Event

In this outcome measure number of participants discontinued from study drug (Epoetin Hospira, Epogen) due to any AE were reported.

Time frame:
Titration Period: Week 1 up to Week 18 and Maintenance Period: Week 19 up to Week 38
Reported as:
Count of participants · Participants
Number of Participants That Discontinued Treatment Due to a Treatment Emergent Adverse Event
ParticipantsEpoetin Hospira: Titration PeriodEpogen: Titration PeriodEpoetin Hospira: Maintenance PeriodEpogen: Maintenance Period
Number of Participants That Discontinued Treatment Due to a Treatment Emergent Adverse Event4644
Other pre-specifiedNumber of Participants With Clinically Significant Change From Baseline in Laboratory Parameters

Laboratory parameters: Hematology (hematocrit, hemoglobin, red blood cell count, reticulocytes, white blood cell count, neutrophils, bands, lymphocytes, monocytes, basophils, eosinophils, platelet count, mean corpuscular volume); coagulation panel (prothrombin time, international normalized ratio, activated partial thromboplastin time); clinical chemistry (blood urea nitrogen, creatinine, alanine aminotransferase, aspartate aminotransferase, total bilirubin, gamma-glutamyl transpeptidase, alkaline phosphatase, sodium, potassium, calcium, magnesium, phosphorus, uric acid, total protein, glucose, albumin, C-reactive protein, plasma ferritin, transferrin saturation). Participants with clinically significant change from baseline in laboratory parameters were as determined by the investigator.

Time frame:
Titration Period: Baseline (Pre-dose on Week 1) up to Week 18 and Maintenance Period: Baseline (Pre-dose on Week 19) up to Week 38
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Change From Baseline in Laboratory Parameters
ParticipantsEpoetin Hospira: Titration PeriodEpogen: Titration PeriodEpoetin Hospira: Maintenance PeriodEpogen: Maintenance Period
Number of Participants With Clinically Significant Change From Baseline in Laboratory Parameters0000
Other pre-specifiedNumber of Participants With Clinically Significant Change From Baseline in Vital Signs

Vital sign parameters: temperature (oral, tympanic, or other), blood pressure (diastolic and systolic), heart rate (in a seated position) and dry weight (post-dialysis). Participants with clinically significant change from baseline in vital signs were as determined by the investigator.

Time frame:
Titration Period: Baseline (Pre-dose on Week 1) up to Week 18 and Maintenance Period: Baseline (Pre-dose on Week 19) up to Week 38
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Change From Baseline in Vital Signs
ParticipantsEpoetin Hospira: Titration PeriodEpogen: Titration PeriodEpoetin Hospira: Maintenance PeriodEpogen: Maintenance Period
Number of Participants With Clinically Significant Change From Baseline in Vital Signs0000
Other pre-specifiedNumber of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG)

ECG parameters: PR interval, QRS complex, QT interval and QTC interval. Participants with clinically significant change from baseline in ECG were as determined by the investigator.

Time frame:
Titration Period: Baseline (Pre-dose on Week 1) up to Week 18 and Maintenance Period: Baseline (Pre-dose on Week 19) up to Week 38
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG)
ParticipantsEpoetin Hospira: Titration PeriodEpogen: Titration PeriodEpoetin Hospira: Maintenance PeriodEpogen: Maintenance Period
Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG)0000
Other pre-specifiedNumber of Participants With Clinically Significant Change From Baseline in Physical Examination

Physical examination included examination of the following: skin, eyes, ears, throat, cardiac, respiratory, gastrointestinal, genitourinary and musculoskeletal systems. Participants with clinically significant change from baseline in physical examination were as determined by the investigator.

Time frame:
Titration Period: Baseline (Pre-dose on Week 1) up to Week 18 and Maintenance Period: Baseline (Pre-dose on Week 19) up to Week 38
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Change From Baseline in Physical Examination
ParticipantsEpoetin Hospira: Titration PeriodEpogen: Titration PeriodEpoetin Hospira: Maintenance PeriodEpogen: Maintenance Period
Number of Participants With Clinically Significant Change From Baseline in Physical Examination0000
Other pre-specifiedPercentage of Participants With Anti-Recombinant Human Erythropoietin (Anti-rhEPO) Antibodies

Percentage of participants with presence of anti-rhEPO antibodies were reported in this outcome measure. Radioimmunoprecipitation assay method was used to determine the presence of anti-rhEPO antibodies.

Time frame:
Titration Period: Week 1 up to Week 18 and Maintenance Period: Week 19 up to Week 38
Reported as:
Number · percentage of participants
Percentage of Participants With Anti-Recombinant Human Erythropoietin (Anti-rhEPO) Antibodies
percentage of participantsEpoetin Hospira: Titration PeriodEpogen: Titration PeriodEpoetin Hospira: Maintenance PeriodEpogen: Maintenance Period
Percentage of Participants With Anti-Recombinant Human Erythropoietin (Anti-rhEPO) Antibodies0.00.00.00.0
Other pre-specifiedPercentage of Participants With General Tolerability

General tolerability was classified as: 1) excellent tolerability = no reaction, 2) good tolerability = minimal reaction, 3) mild intolerability = reaction above that normally observed with any kind of subcutaneous product, 4) moderate intolerability = marked reaction, but no need for discontinuation of treatment and 5) severe intolerability = treatment discontinued due to intolerability.

Time frame:
Titration Period: Week 1 up to Week 18 and Maintenance Period: Week 19 up to Week 38
Reported as:
Number · percentage of participants
Percentage of Participants With General Tolerability
percentage of participantsEpoetin Hospira: Titration PeriodEpogen: Titration PeriodEpoetin Hospira: Maintenance PeriodEpogen: Maintenance Period
Excellent Tolerability68.867.463.950.8
Good Tolerability28.825.627.027.9
Mild Intolerability2.52.34.916.4
Moderate Intolerability0.02.30.02.5
Severe Intolerability0.00.01.61.6
Other pre-specifiedPercentage of Participants With Local Tolerability

Local tolerability was classified as: 1) excellent tolerability = no reaction at site of injection, 2) good tolerability = minimal reaction at site of injection normally observed with any kind of subcutaneous product, 3) mild intolerability = reaction at site of injection above that normally observed with any kind of subcutaneous product, 4) moderate intolerability = marked reaction, but no need for discontinuation of treatment and 5) severe intolerability = treatment discontinued due to intolerability.

Time frame:
Titration Period: Week 1 up to Week 18 and Maintenance Period: Week 19 up to Week 38
Reported as:
Number · percentage of participants
Percentage of Participants With Local Tolerability
percentage of participantsEpoetin Hospira: Titration PeriodEpogen: Titration PeriodEpoetin Hospira: Maintenance PeriodEpogen: Maintenance Period
Excellent Tolerability70.066.367.254.1
Good Tolerability25.025.624.630.3
Mild Intolerability3.85.84.19.0
Moderate Intolerability1.31.21.63.3
Severe Intolerability0.00.00.02.5

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Epoetin Hospira: Titration Period—12/80 (15%)16/80 (20%)
Epogen: Titration Period—22/86 (25.6%)10/86 (11.6%)
Epoetin Hospira: Maintenance Period—23/122 (18.9%)27/122 (22.1%)
Epogen: Maintenance Period—33/122 (27%)24/122 (19.7%)
Most frequent serious events
Showing 10 of 101
Most frequent serious events
EventEpoetin Hospira: Titration PeriodEpogen: Titration PeriodEpoetin Hospira: Maintenance PeriodEpogen: Maintenance Period
HypoglycaemiaMetabolism and nutrition disorders0/800/860/1224/122
SepsisInfections and infestations2/802/860/1220/122
Uterine LeiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/401/400/590/67
Vulval CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/400/400/590/67
Vulval Cancer Stage 0Neoplasms benign, malignant and unspecified (incl cysts and polyps)0/401/400/590/67
MenorrhagiaReproductive system and breast disorders0/401/400/590/67
PneumoniaInfections and infestations1/801/863/1222/122
Acute Myocardial InfarctionCardiac disorders0/802/860/1220/122
Chronic Obstructive Pulmonary DiseaseRespiratory, thoracic and mediastinal disorders0/802/860/1220/122
Atrial FibrillationCardiac disorders0/801/861/1222/122
Most frequent other events
Most frequent other events
EventEpoetin Hospira: Titration PeriodEpogen: Titration PeriodEpoetin Hospira: Maintenance PeriodEpogen: Maintenance Period
NauseaGastrointestinal disorders0/800/8610/1228/122
DizzinessNervous system disorders4/800/863/1228/122
FallInjury, poisoning and procedural complications0/800/868/1223/122
Injection Site PainGeneral disorders0/800/863/1228/122
PyrexiaGeneral disorders0/800/868/1223/122
Procedural HypotensionInjury, poisoning and procedural complications5/802/860/1220/122
Muscle SpasmsMusculoskeletal and connective tissue disorders0/805/860/1220/122
HeadacheNervous system disorders4/804/860/1220/122
HyperkalaemiaMetabolism and nutrition disorders4/801/860/1220/122
Eosinophil Count IncreasedInvestigations4/800/860/1220/122

Baseline characteristics

Analysis population included all participants who were enrolled.

Age, Categorical
Age, Categorical(Participants)Epoetin HospiraEpogenTotal
<=18 years000
Between 18 and 65 years109117226
>=65 years514394
Sex: Female, Male
Sex: Female, Male(Participants)Epoetin HospiraEpogenTotal
Female7784161
Male8376159
08

Study locations

73 sites
  • North America Research Institute
    Azusa, California 91702, United States
  • National Institute of Clinical Research
    Bakersfield, California 93309, United States
  • Long Beach Dialysis Center
    Long Beach, California 90813, United States
  • Academic Medical Research Institute
    Los Angeles, California 90022, United States
  • Long Beach Dialysis Center
    Modesto, California 95350, United States
  • Innovative Dialysis Center of Northridge, LLC
    Northridge, California 91324, United States
  • Valley Renal Medical Group
    Northridge, California 91324, United States
  • Research Management Inc.
    Paramount, California 90723, United States
  • Pleasanton Dialysis Center
    Pleasanton, California 94588, United States
  • Sunset Dialysis Center
    Rancho Cordova, California 95670, United States
  • Capital Nephrology Medical Group
    Sacramento, California 95825, United States
  • Chabot Nephrology Medical Group
    San Leandro, California 94578, United States
  • San Leandro Dialysis
    San Leandro, California 94578, United States
  • Renal Consultants Medical Group
    Santa Clarita, California 91387, United States
  • Intercommunity Dialysis Center
    Whittier, California 90602, United States
  • American Institute of Research
    Whittier, California 90603, United States
  • Whittier Kidney Dialysis Center
    Whittier, California 90603, United States
  • Western Nephrology and Metabolic Bone Disease, PC
    Arvada, Colorado 80002, United States
  • Kidney Center of Westminster, LLC
    Westminster, Colorado 80031, United States
  • Western Nephrology and Metabolic Bone Disease, PC
    Westminster, Colorado 80031, United States
  • Pines Clinical Research Inc.
    Pembroke Pines, Florida 33028, United States
  • Dialysis Clinic, Inc. - Albany
    Albany, Georgia 31701-2057, United States
  • Kidney Care Associates
    Augusta, Georgia 30909, United States
  • Renal Physicians of Georgia, PC
    Dublin, Georgia 31021, United States
  • Neomedica Marquette Park
    Chicago, Illinois 60636, United States
  • Research by Design, LLC
    Evergreen Park, Illinois 60805, United States
  • Kansas Nephrology Physicians, PA
    Wichita, Kansas 67214, United States
  • Research Nurse Specialists, LLC
    Lafayette, Louisiana 70503, United States
  • New York Harbor Health Care System
    Lafayette, Louisiana 70506, United States
  • Westbank Nephrology Associates
    Marrero, Louisiana 70072, United States
  • FMC Opelousas
    Opelousas, Louisiana 70570, United States
  • Northwest Louisiana Nephrology
    Shreveport, Louisiana 71101, United States
  • Fresenius Medical Care-Kalamazoo East
    Kalamazoo, Michigan 49001, United States
  • Fresenius Medical Care-Kalamazoo
    Kalamazoo, Michigan 49007, United States
  • Nephrology Center DBA Paragon Health PC
    Kalamazoo, Michigan 49007, United States
  • Fresenius Medical Care-Oshtemo
    Kalamazoo, Michigan 49009, United States
  • Fresenius Medical Care-Gull Road
    Kalamazoo, Michigan 49048, United States
  • Clinical Research Consultants, LLC
    Kansas City, Missouri 64111, United States
  • Kansas City Renal Center
    Kansas City, Missouri 64111, United States
  • Renal Advantage, Inc.
    Kansas City, Missouri 64131, United States
  • Metro Hypertension and Kidney Center
    Saint Louis, Missouri 63136, United States
  • University of Cincinnati College of Medicine.
    North Brunswick, New Jersey 08902, United States
  • Nephrology & Hypertension Associates of NJ
    Voorhees, New Jersey 08043, United States
  • Newtown Dialysis Center
    Astoria, New York 11102, United States
  • New York Hospital Medical Center Queens Institutional Review Board
    Flushing, New York 11355, United States
  • Parker Jewish Institute for Health Care and Rehabilitation
    New Hyde Park, New York 11040, United States
  • New York Harbor Health Care System
    New York, New York 10010, United States
  • Wake Nephrology Associates, PA
    Raleigh, North Carolina 27609, United States
  • University of Cincinnati College of Medicine
    Cincinnati, Ohio 45267, United States
  • Private Practice of Kenneth Lempert
    Toledo, Ohio 43606, United States
  • Northwest Physicians Associates, PC
    Meadville, Pennsylvania 16335, United States
  • CSRA Renal Services, LLC
    Aiken, South Carolina 29801, United States
  • Fresenius Medical Care Midtown JV
    Columbia, South Carolina 29201, United States
  • Columbia Nephrology Associates, PA
    Columbia, South Carolina 29203, United States
  • Fresenius Medical Care Irmo JV
    Irmo, South Carolina 29063, United States
  • South Carolina Nephrology and Hypertension Center, Inc.
    Orangeburg, South Carolina 29118, United States
  • Knoxville Kidney Center, PLLC
    Knoxville, Tennessee 37923, United States
  • Fresenius Medical Care - Austin North Dialysis
    Austin, Texas 78758, United States
  • Research Management, Inc.
    Austin, Texas 78758, United States
  • Research Management, Inc
    Austin, Texas 78758, United States
  • Dallas Veterans Affairs Medical Center
    Dallas, Texas 75216, United States
  • Grand Prairie Dialysis Center
    Grand Prairie, Texas 75051, United States
  • Research Across America
    Houston, Texas 77054, United States
  • Westminster Dialysis
    Houston, Texas 77077, United States
  • Mission Bend Dialysis
    Houston, Texas 77083, United States
  • Southwest Houston Research, Ltd.
    Houston, Texas 77099, United States
  • East Texas Nephrology Associates
    Lufkin, Texas 75904, United States
  • San Antonio Kidney Disease Center
    San Antonio, Texas 78229, United States
  • Renal Care Partners of Pentagon City
    Arlington, Virginia 22206, United States
  • Clinical Research and Consulting Center, LLC
    Fairfax, Virginia 22030, United States
  • Renal Care Partners of Fairfax
    Fairfax, Virginia 22030, United States
  • Nephrology Specialists, PC
    Mechanicsville, Virginia 23116, United States
  • Western Institutional Review Board
    Olympia, Washington 98502, United States
09

References and documents

Publications

  • Wish JB, Rocha MG, Martin NE, Reyes CRD, Fishbane S, Smith MT, Nassar G. Long-term Safety of Epoetin Alfa-epbx for the Treatment of Anemia in ESKD: Pooled Analyses of Randomized and Open-label Studies. Kidney Med. 2019 Aug 28;1(5):271-280. doi: 10.1016/j.xkme.2019.06.009. eCollection 2019 Sep-Oct. PubMed 32734207 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2012 to primary completion in Feb 2014, 25 months.

Results were first posted in Jun 2018, 4 years 3 months after primary completion. A results delay was requested in Feb 2015.

Of 42 industry-sponsored phase 3 interventional studies under Kidney Failure, Chronic, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 40. This study's 25 months is below that.

Counting every sponsor, half of 66 studies reached it within 32 months; a quarter within 21 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2011
First posted
Nov 17, 2011
StartActual
Jan 17, 2012
Primary completionActual
Feb 28, 2014
CompletionActual
Feb 28, 2014
Results delay requested
Feb 23, 2015
Results first posted
Jun 20, 2018
Last update
Aug 9, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 9, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01473420
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Nov 17, 2011
Start date
Jan 17, 2012
Primary completion
Feb 28, 2014
Completion
Feb 28, 2014
Results posted
Jun 20, 2018
Last update
Aug 9, 2018

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Epoetin Alfa

Start the discussion